Post-traumatic stress disorder (PTSD) can cause an array of adverse mental health effects, but physical side effects are also common.
Vous n'êtes pas connecté
A US company seeking to use MDMA capsules to treat post-traumatic stress disorder has said federal regulators rejected the bid. Lykos Therapeutics said the FDA requested an additional Phase 3 trial to gather more data.
Post-traumatic stress disorder (PTSD) can cause an array of adverse mental health effects, but physical side effects are also common.
MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
More hospitals and clinics now offer patients ketamine therapy for severe depression, post-traumatic stress disorder and other mental health...
Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
From Aug. 11 to 19, Sgt. Rob Nederlof pedalled the highways between Edmonton and Regina on his bike. This was the fourth year for the ride, which...